← All daily entries

Tuesday, August 11, 2026

CRISPR

Today's trivia

1. Who first spotted the mysterious repeated DNA sequences later named CRISPR, while studying E. coli in 1987, decades before anyone knew what they did?

Answer Yoshizumi Ishino

While sequencing a gene involved in alkaline phosphatase conversion, Japanese researcher Yoshizumi Ishino and his team noticed an unusual set of short, repeated DNA sequences interrupted by unique spacer segments — an oddity they duly reported but couldn't explain. Genome sequencing was still primitive at the time, so there was no way to compare the pattern against other organisms or guess its purpose. It would take another two decades, and the discovery of similar repeats across many other bacterial species, before anyone understood what these sequences were actually for.

2. What food company's research into yogurt- and cheese-fermenting bacteria first revealed that CRISPR works as a bacterial immune system against viruses?

Answer Danisco

At the industrial food company Danisco, scientists Rodolphe Barrangou and Philippe Horvath weren't trying to invent a gene-editing tool — they were trying to stop viral outbreaks from wiping out the bacterial starter cultures used to make yogurt and cheese. Studying Streptococcus thermophilus, they found that CRISPR spacer sequences matched fragments of DNA from viruses that had previously attacked the bacteria, and that bacteria carrying a matching spacer were immune to that specific virus. Their 2007 paper was the first direct evidence that CRISPR functions as an adaptive immune system, and it came out of dairy-industry research rather than a genetics lab chasing gene editing.

3. About how many years passed between CRISPR's accidental discovery in bacterial DNA and scientists confirming it functions as an antiviral defense system?

Answer 20

Ishino's team logged the strange repeated sequences in 1987, but the field had no framework for interpreting them until comparative genomics matured enough to spot the same pattern across many bacterial and archaeal species. It wasn't until Barrangou and Horvath's 2007 Danisco study that anyone experimentally confirmed CRISPR's role as a virus-fighting immune mechanism. That two-decade gap between spotting an oddity and understanding its function is part of why CRISPR's eventual repurposing as a precision gene-editing tool, just a few years later, felt so sudden to the public.

4. Which gene does Casgevy, the first FDA-approved CRISPR-based therapy, edit in patients to treat sickle cell disease?

Answer BCL11A

Casgevy, approved by UK regulators in November 2023 and the FDA that December, doesn't fix the mutated hemoglobin gene that actually causes sickle cell disease. Instead it edits a regulatory region of the BCL11A gene in a patient's own stem cells, which normally suppresses production of fetal hemoglobin after infancy. Switching that suppression off lets the body resume making fetal hemoglobin, which doesn't sickle the way adult hemoglobin does, effectively working around the disease rather than repairing its root cause.

5. In 2020, Emmanuelle Charpentier and Jennifer Doudna became the first all-female duo to share a Nobel Prize in what category, for their work on CRISPR-Cas9?

Answer Chemistry

Charpentier and Doudna won the 2020 Nobel Prize in Chemistry for developing CRISPR-Cas9 as a programmable gene-editing tool, less than a decade after their foundational 2012 paper. It was the first Nobel science prize ever shared by two women without a male co-recipient, a milestone that drew almost as much attention as the discovery itself. The speed of the award was also notable — many Nobel-worthy discoveries wait decades for recognition, but CRISPR's impact on research and medicine was judged obvious well within ten years of publication.

← All daily entries